

# BINAXNOW<sup>™</sup> MALARIA

With malaria, a life could depend on the ability to make an accurate differential diagnosis.

Aids in the diagnosis of *Plasmodium falciparum* infection versus pan-malarial infection caused by *Plasmodium vivax, Plasmodium ovale* or *Plasmodium malariae* 

## MALARIA: KEY FACTS

The Asia-Pacific region accounts for nearly 70% of the burden outside the World Health Organisation (WHO) African region. The prevalence of P. falciparum and P. vivax varies by country but on average is around 60% and 40%, respectively. Within this region, India and Indonesia accounted for 80% and 16% of the reported cases and 60% and 30% of malaria deaths in 2016, respectively.<sup>1</sup>



## 3.3 BILLION

Almost half the world is at risk of malaria. In 2016, the African region was home to 90% of malaria cases.<sup>1</sup>



## 216 MILLION

Cases in 2016, compared to 211 million cases in 2015.<sup>1</sup>



Deaths in 2016. Of these, roughly two-thirds were children under 5 years of age.<sup>1,2</sup>



As per WHO recommendation, all cases of suspected malaria need to be confirmed by diagnostic testing prior to providing treatment.<sup>3</sup>

#### **BINAXNOW™ MALARIA**

#### **TOTAL TIME: 15 MINUTES**

Obtain blood

Add blood and reagent to card

Close card and read results in 15 minutes

For fast, qualitative detection of antigens to four species of malaria: *P. falciparum*, *P. vivax*, *P. malariae* and *P. ovale* 

#### RAPID

• Results seen in 15 minutes, enabling immediate treatment

#### EASY TO USE

- Simple-to-use test using only one reagent
- Requires just a small blood sample easily collected by fingerprick
- No need for skilled microscopist

#### EASY TO INTERPRET

- Differentiated results that aid in the diagnosis of lethal *P. falciparum* infection
- Objective, qualitative results
- No subjective assessment required

#### ACCURATE AND RELIABLE

- High specificity and sensitivity
- Built-in procedural control ensures test viability
- Reduces unnecessary use of antimalarial drugs, thereby helping to minimise the development of drug-resistant malaria strains





### BinaxNOW<sup>™</sup> Malaria Test

#### HIGHLY SENSITIVE AND SPECIFIC FOR DETECTION OF MALARIA INFECTION



Procedure shown is for a capillary blood sample. For complete Instructions for Use, see the Package Insert.

#### **READING RESULTS**



**FINGERSTICK SAMPLES** 

% Sensitivity

98.8%

80.6%

*P.f.* 

P.v.

95% CI

94%-100%

73%-87%

% Specificity

90.4%

99.5%

<b>POSITIVE</b> P.f.	<b>POSITIVE</b> P.v., P.m., P.o.

95% CI

88%-92%

99%-100%

#### NEGATIVE



PRODUCT INFORMATION	
PRODUCT	ORDER NUMBER
BinaxNOW™Malaria Test 5 Test Kit	66005
BinaxNOW™ Malaria Test 25 Test Kit	660-000

**OTHER BINAXNOW<sup>™</sup> TESTS** 

BINAXNOW<sup>™</sup> INFLUENZA A & B (NOT AVAILABLE IN THE UNITED STATES) BINAXNOW<sup>™</sup> LEGIONELLA BINAXNOW<sup>™</sup> RSV BINAXNOW<sup>™</sup> S. PNEUMONIAE BINAXNOW<sup>™</sup> STREP A BINAXNOW<sup>™</sup> G6PD ALERE FILARIASIS (NOT AVAILABLE IN THE UNITED STATES)

CI = confidence interval

1. WHO Malaria Report 2017. http://www.who.int/malaria/publications/world-malaria-report-2017/report/en 2. https://data.unicef.org/topic/child-health/malaria/

3. https://www.who.int/news-room/fact-sheets/detail/malaria

© 2020 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. 12000428-03 08/20

